NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
NeurAxis Coverage Announcement: NeurAxis, Inc. has announced medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, which is now covered by two health insurers in Connecticut and Massachusetts, expanding total coverage to approximately 53 million members nationwide.
Technology and Future Plans: The IB-Stim device, FDA-cleared for treating functional abdominal pain in adolescents, aims to improve accessibility and affordability of treatment, with plans for broader adoption following the activation of a new CPT code in January 2026 and ongoing clinical trials for additional conditions.
Trade with 70% Backtested Accuracy
Analyst Views on NRXS
About NRXS
About the author
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone
Management Insights: NeurAxis, Inc. is focused on executing its commercialization strategy for IB-Stim and RED, with a priority on securing medical policy coverage ahead of the new Category 1 CPT code effective January 1, 2026. The company is expanding its market opportunities and has seen positive payer momentum, with approximately 55 million covered lives.
Financial Performance: In Q3 2025, NeurAxis reported revenues of $811,000, a 22% increase year-over-year, and unit deliveries rose by 38%. However, operating expenses increased significantly, leading to an operating loss of $2.1 million, reflecting ongoing investments in sales and marketing.
Outlook and Growth Strategy: Management anticipates continued revenue growth into Q4 2025, driven by strong demand from healthcare providers and patients. They are implementing a three-pronged commercial plan for IB-Stim and addressing challenges in the adoption of RED due to changes in physician practice habits.
Risks and Concerns: The company acknowledges potential risks related to slow payer adoption and the challenges of changing physician practices for RED. Operating expenses and cash burn remain concerns, but management is focused on cost control while preparing for anticipated growth catalysts in 2026.
NeurAxis Inc Reports Increased Losses in Q3
- Earnings Overview: NeurAxis Inc reported a third-quarter loss of $2.12 million, an increase from a loss of $1.76 million in the same period last year.
- Revenue Growth: The company's revenue rose by 20.9% to $0.81 million, compared to $0.67 million in the previous year.
NeurAxis Achieves Impressive Financial Performance in Q3 2025 with 22% Revenue Growth
Financial Performance: NeurAxis reported a 22% increase in revenues for Q3 2025, totaling $811 thousand, but also experienced a 27% rise in operating loss due to increased sales and marketing expenses.
FDA Clearances: The company received its first FDA clearance for treating pain in Functional Dyspepsia and expanded its IB-Stim device's indications to include patients aged 8-21, significantly broadening its market potential.
Operational Growth: NeurAxis expanded its total covered lives to approximately 55 million and secured a new CPT Category I code for PENFS procedures, effective January 1, 2026, enhancing reimbursement prospects.
Management Outlook: CEO Brian Carrico expressed optimism for substantial revenue growth in 2026, driven by expanded insurance coverage and increased demand for their proprietary PENFS technology.
Zacks Analyst Blog Features Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis
Featured Stocks: Zacks.com highlights stocks such as Alphabet Inc., IBM Corp., Merck & Co., SandRidge Energy, and NeurAxis in their Analyst Blog, providing insights into their recent performance and market trends.
Research Reports: The Zacks Research Daily includes detailed reports on 16 major stocks, emphasizing Alphabet's growth in AI and cloud services, IBM's focus on hybrid cloud and AI, Merck's challenges with drug competition, and the promising outlook for micro-cap stocks SandRidge and NeurAxis.
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone
Management Insights: NeurAxis, Inc. is focused on executing its commercialization strategy for IB-Stim and RED, with a priority on securing medical policy coverage ahead of the new Category 1 CPT code effective January 1, 2026. The company is expanding its market opportunities and has seen positive payer momentum, with approximately 55 million covered lives.
Financial Performance: In Q3 2025, NeurAxis reported revenues of $811,000, a 22% increase year-over-year, and unit deliveries rose by 38%. However, operating expenses increased significantly, leading to an operating loss of $2.1 million, reflecting ongoing investments in sales and marketing.
Outlook and Growth Strategy: Management anticipates continued revenue growth into Q4 2025, driven by strong demand from healthcare providers and patients. They are implementing a three-pronged commercial plan for IB-Stim and addressing challenges in the adoption of RED due to changes in physician practice habits.
Risks and Concerns: The company acknowledges potential risks related to slow payer adoption and the challenges of changing physician practices for RED. Operating expenses and cash burn remain concerns, but management is focused on cost control while preparing for anticipated growth catalysts in 2026.
NeurAxis Inc Reports Increased Losses in Q3
- Earnings Overview: NeurAxis Inc reported a third-quarter loss of $2.12 million, an increase from a loss of $1.76 million in the same period last year.
- Revenue Growth: The company's revenue rose by 20.9% to $0.81 million, compared to $0.67 million in the previous year.
NeurAxis Achieves Impressive Financial Performance in Q3 2025 with 22% Revenue Growth
Financial Performance: NeurAxis reported a 22% increase in revenues for Q3 2025, totaling $811 thousand, but also experienced a 27% rise in operating loss due to increased sales and marketing expenses.
FDA Clearances: The company received its first FDA clearance for treating pain in Functional Dyspepsia and expanded its IB-Stim device's indications to include patients aged 8-21, significantly broadening its market potential.
Operational Growth: NeurAxis expanded its total covered lives to approximately 55 million and secured a new CPT Category I code for PENFS procedures, effective January 1, 2026, enhancing reimbursement prospects.
Management Outlook: CEO Brian Carrico expressed optimism for substantial revenue growth in 2026, driven by expanded insurance coverage and increased demand for their proprietary PENFS technology.
Zacks Analyst Blog Features Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis
Featured Stocks: Zacks.com highlights stocks such as Alphabet Inc., IBM Corp., Merck & Co., SandRidge Energy, and NeurAxis in their Analyst Blog, providing insights into their recent performance and market trends.
Research Reports: The Zacks Research Daily includes detailed reports on 16 major stocks, emphasizing Alphabet's growth in AI and cloud services, IBM's focus on hybrid cloud and AI, Merck's challenges with drug competition, and the promising outlook for micro-cap stocks SandRidge and NeurAxis.
